Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes

References

• BishopHMBlameyRWA suggested classification of breast painPostgrad Med J197955Suppl 55960231775
   PubMedGoogle Scholar
• HaybittleJLBlameyRWElstonCWA prognostic index in primary breast cancerBr J Cancer19824533613667073932
   PubMed Web of Science ®Google Scholar
• WilliamsCBrunskillSAltmanDCost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapyHealth Technol Assess20061034iiiivixxi1204
   Web of Science ®Google Scholar
• GoldhirschAWoodWCCoatesASPanel MembersStrategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Ann Oncol20112281736174721709140
   PubMed Web of Science ®Google Scholar
• GoldhirschAGlickJHGelberRDSennHJMeeting highlights: International Consensus Panel on the Treatment of Primary Breast CancerJ Natl Cancer Inst19989021160116089811309
   PubMedGoogle Scholar
• EifelPAxelsonJACostaJNational Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000J Natl Cancer Inst2001931397998911438563
   PubMed Web of Science ®Google Scholar
• McGuireWLBreast cancer prognostic factors: evaluation guidelinesJ Natl Cancer Inst19918331541551988696
   PubMed Web of Science ®Google Scholar
• HayesDFDo we need prognostic factors in nodal-negative breast cancer? ArbiterEur J Cancer200036330230610708930
   PubMed Web of Science ®Google Scholar
• FisherERCostantinoJFisherBRedmondCPathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project InvestigatorsCancer1993716 Suppl214121508443763
   PubMedGoogle Scholar
• FisherBRedmondCPoissonREight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancerN Engl J Med1989320138228282927449
   PubMed Web of Science ®Google Scholar
• FisherERAndersonSRedmondCFisherBPathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-Year pathologic and clinical prognostic discriminantsCancer1993718250725148453574
   PubMed Web of Science ®Google Scholar
• RosenPPGroshenSSaigoPEKinneDWHellmanSPathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 yearsJ Clin Oncol198979123912512549203
   PubMed Web of Science ®Google Scholar
• FisherBBryantJWolmarkNEffect of preoperative chemotherapy on the outcome of women with operable breast cancerJ Clin Oncol1998168267226859704717
   PubMed Web of Science ®Google Scholar
• BearHDAndersonSSmithRESequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol200624132019202716606972
   PubMed Web of Science ®Google Scholar
• RakhaEALeeAHEvansAJTubular carcinoma of the breast: further evidence to support its excellent prognosisJ Clin Oncol20102819910419917872
   PubMed Web of Science ®Google Scholar
• CaldarellaABuzzoniCCrocettiEInvasive breast cancer: a significant correlation between histological types and molecular subgroupsJ Cancer Res Clin Oncol2013139461762323269487
   PubMed Web of Science ®Google Scholar
• DieciMVOrvietoEDominiciMContePGuarneriVRare breast cancer subtypes: histological, molecular, and clinical peculiaritiesOncologist201419880581324969162
   PubMed Web of Science ®Google Scholar
• BerryDACirrincioneCHendersonICEstrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerJAMA2006295141658166716609087
   PubMed Web of Science ®Google Scholar
• VoogdACNielsenMPeterseJLDanish Breast Cancer Cooperative GroupBreast Cancer Cooperative Group of the European Organization for Research and Treatment of CancerDifferences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trialsJ Clin Oncol20011961688169711250998
   PubMed Web of Science ®Google Scholar
• CookeTReevesJLaniganAStantonPHER2 as a prognostic and predictive marker for breast cancerAnn Oncol200112Suppl 1S23S2811521717
   PubMedGoogle Scholar
• BonadonnaGValagussaPMoliterniAZambettiMBrambillaCAdjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-upN Engl J Med1995332149019067877646
   PubMed Web of Science ®Google Scholar
• RavdinPMSiminoffLADavisGJComputer program to assist in making decisions about adjuvant therapy for women with early breast cancerJ Clin Oncol200119498099111181660
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative GroupLancet19983519114145114679605801
   PubMed Web of Science ®Google Scholar
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative GroupLancet199835291329309429752815
   PubMed Web of Science ®Google Scholar
• OlivottoIABajdikCDRavdinPMPopulation-based validation of the prognostic model ADJUVANT! For early breast cancerJ Clin Oncol200523122716272515837986
   PubMed Web of Science ®Google Scholar
• ChangHYNuytenDSSneddonJBRobustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survivalProc Natl Acad Sci U S A2005102103738374315701700
   PubMed Web of Science ®Google Scholar
• van de VijverMJHeYDvan’t VeerLJA gene-expression signature as a predictor of survival in breast cancerN Engl J Med2002347251999200912490681
   PubMed Web of Science ®Google Scholar
• FoekensJAAtkinsDZhangYMulticenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancerJ Clin Oncol200624111665167116505412
   PubMed Web of Science ®Google Scholar
• BryantJFisherBGunduzNCostantinoJPEmirBS-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancerBreast Cancer Res Treat199851323925310068082
   PubMed Web of Science ®Google Scholar
• HendersonICPatekAJThe relationship between prognostic and predictive factors in the management of breast cancerBreast Cancer Res Treat1998521–326128810066087
   PubMed Web of Science ®Google Scholar
• EstevaFJHortobagyiGNPrognostic molecular markers in early breast cancerBreast Cancer Res20046310911815084231
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med2004351272817282615591335
   PubMed Web of Science ®Google Scholar
• HabelLAShakSJacobsMKA population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patientsBreast Cancer Res200683R2516737553
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJRedmondCA randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumorsN Engl J Med198932084794842644532
   PubMed Web of Science ®Google Scholar
• FisherBDignamJWolmarkNTamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancerJ Natl Cancer Inst19978922167316829390536
   PubMedGoogle Scholar
• FisherBJeongJHBryantJNational Surgical Adjuvant Breast and Bowel Project Randomised Clinical TrialsTreatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsLancet2004364943785886815351193
   PubMed Web of Science ®Google Scholar
• PaikSTangGShakSGene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerJ Clin Oncol200624233726373416720680
   PubMed Web of Science ®Google Scholar
• AlbainKSBarlowWEShakSBreast Cancer Intergroup of North AmericaPrognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialLancet Oncol2010111556520005174
   PubMed Web of Science ®Google Scholar
• LiebermanNBaehnerFLSoussan-GutmanLEvaluation of Recurrence Score, Nodal Status and Traditional Clinicopathologic Metrics in a Large ER Positive Patient CohortProvidence, RIEuropean Society of Medical Oncology2011 Abstract #1420
   Google Scholar
• RavdinPControversies in Early Breast CancerSABCSSan Antonio, CA, USA2011
   Google Scholar
• van’t VeerLJDaiHvan de VijverMJGene expression profiling predicts clinical outcome of breast cancerNature2002415687153053611823860
   PubMed Web of Science ®Google Scholar
• SimonRMPaikSHayesDFUse of archived specimens in evaluation of prognostic and predictive biomarkersJ Natl Cancer Inst2009101211446145219815849
   PubMed Web of Science ®Google Scholar
• BuyseMLoiSvan’t VeerLTRANSBIG ConsortiumValidation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerJ Natl Cancer Inst200698171183119216954471
   PubMed Web of Science ®Google Scholar
• NielsenTOParkerJSLeungSA comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancerClin Cancer Res201016215222523220837693
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• DowsettMSestakILopez-KnowlesEComparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapyJ Clin Oncol201331222783279023816962
   PubMed Web of Science ®Google Scholar
• RossDTKimCYTangGChemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trialsClin Cancer Res200814206602660918927301
   PubMed Web of Science ®Google Scholar
• BartlettJMThomasJRossDTMammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyBreast Cancer Res2010124R4720615243
   PubMed Web of Science ®Google Scholar
• BartlettJMBloomKJPiperTMammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology studyJ Clin Oncol201230364477448423045591
   PubMed Web of Science ®Google Scholar
• BartlettJMSBloomKJGoldsteinNSMammostrat^® as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology StudySABCS2010 Poster/Abstract: P3-10-33
   Google Scholar
• CloughKBPouletBJamshidianFRisk Classification of Early Stage Breast Cancer as Assessed by MammaPrint and Oncotype DX Genomic AssaySABCS2012 Poster/Abstract: p6-07-03
   Google Scholar
• ShiversSCClarkLEsposito NHDirect comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancerSABCS2013 Poster/Abstract: P6-06-02
   Google Scholar
• KellyCMBernardPSKrishnamurthySAgreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX(R)) and the PAM50 breast cancer intrinsic Classifier in early-stage estrogen receptor-positive breast cancerOncologist201217449249822418568
   PubMed Web of Science ®Google Scholar
• CardosoFPiccart-GebhartMVan’t VeerLRutgersEConsortiumTThe MINDACT trial: the first prospective clinical validation of a genomic toolMol Oncol20071324625119383299
   PubMed Web of Science ®Google Scholar
• RutgersEPiccart-GebhartMJBogaertsJThe EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phaseEur J Cancer201147182742274922051734
   PubMed Web of Science ®Google Scholar
• Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node negative breast cancer (the TAILORx Trial) Clinical Trial ID: NCT00310180. Available from: https://clinicaltrials.gov/ct2/show/NCT00310180Accessed June 24, 2015
   Google Scholar
• A phase III, radomized clinical trial of standard adjuvant endocrine therapy +/− chemotherapy in patients with 1–3 positive nodes, hormone receptor-positive and HER2− negative breast cancer with a recurrence score (RS) of 25 or less. RxPONDER: a clinical trial RX for positive node, endocrine responsive breast cancer Clinical Trial ID NCT01272037. Available from: https://clinicaltrials.gov/ct2/show/NCT01272037
   Google Scholar